Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776672 | 0.83 | TSHR (0.35) | — | |
| SCHEMBL820644 | 0.83 | — | — | |
| SCHEMBL27541092 | 0.81 | LOXL2 (0.31) | — | |
| SCHEMBL1777957 | 0.81 | GABRA1 (0.38) | GABRA1 | |
| SCHEMBL819202 | 0.80 | KCNH2 (0.32) | — | |
| SCHEMBL177278 | 0.78 | GABRA1 (0.38) | GABRA1 | |
| SCHEMBL60696 | 0.78 | GABRA1 (0.38) | GABRA1GABRG2GABRB3 | |
| SCHEMBL8576128 | 0.77 | KCNH2 (0.42) | — | |
| SCHEMBL1777500 | 0.77 | KCNH2 (0.42) | — | |
| SCHEMBL27844043 | 0.76 | GABRA1 (0.36) | GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563110-B | Quinolinyldiamido transition metal complexes, their production and use | 埃克森美孚化学专利公司 | 2021-08-20 | — | — | CN | claimed |
| EP-3478694-B9 | QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2021-08-04 | — | — | EP | claimed |
| US-10927196-B2 | Long chain branched polypropylene via polymerization with aluminum vinyl transfer agent | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-02-23 | — | — | US | claimed |
| EP-3478694-B1 | QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2020-12-09 | — | — | EP | claimed |
| US-10815318-B2 | Quinolinyldiamido transition metal complexes, production and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-10-27 | — | — | US | claimed |
| US-10562987-B2 | Polymers produced via use of quinolinyldiamido transition metal complexes and vinyl transfer agents | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-02-18 | — | — | US | claimed |
| US-20190177449-A1 | Quinolinyldiamido Transition Metal Complexes, Production and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-06-13 | — | — | US | claimed |
| EP-3478694-A1 | QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109563110-A | Quinolyl diamino transition metal complex, production and purposes | 埃克森美孚化学专利公司 | 2019-04-02 | — | — | CN | claimed |
| US-10208140-B2 | Quinolinyldiamido transition metal complexes, production and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2019-02-19 | — | — | US | claimed |
| WO-2018160276-A1 | POLYMERS PRODUCED VIA USE OF QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES AND VINYL TRANSFER AGENTS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-09-07 | — | — | WO | claimed |
| US-20180134816-A1 | Polymers Produced via Use of Quinolinyldiamido Transition Metal Complexes and Vinyl Transfer Agents | EXXONMOBIL CHEMICAL PATENTS INC. | 2018-05-17 | — | — | US | claimed |
| US-20180002352-A1 | Quinolinyldiamido Transition Metal Complexes, Production and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2018-01-04 | — | — | US | claimed |
| WO-2018005201-A1 | QUINOLINYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-01-04 | — | — | WO | claimed |
| US-20090186876-A1 | Pyridine Analogues II | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | claimed |
| CN-101479256-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2009-07-08 | — | — | CN | claimed |
| EP-2041111-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008002247-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| US-20070244088-A1 | New Pyridine Analogues II | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
| US-5807864-A | INCREASING HIGH DENSITY LIPOPROTEIN LEVELS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208140-B2 | Quinolinyldiamido transition metal complexes, production and use thereof | PARN, PARG, PICALM | GABRA1 3710/4885GABRG2 3594/4885GABRB3 3400/4885 |
| US-20180002352-A1 | Quinolinyldiamido Transition Metal Complexes, Production and Use Thereof | PARN, PARG, PICALM | GABRA1 3710/4885GABRG2 3594/4885GABRB3 3400/4885 |
| US-20070244088-A1 | New Pyridine Analogues II | P2RY12, P2RY1, P2RY11 | GABRA1 1100/4885GABRG2 1174/4885GABRB3 1976/4885 |
| US-10815318-B2 | Quinolinyldiamido transition metal complexes, production and use thereof | PARN, PARG, PICALM | GABRA1 3710/4885GABRG2 3594/4885GABRB3 3400/4885 |
| US-20190177449-A1 | Quinolinyldiamido Transition Metal Complexes, Production and Use Thereof | PARN, PARG, PICALM | GABRA1 3710/4885GABRG2 3594/4885GABRB3 3400/4885 |
| US-20090186876-A1 | Pyridine Analogues II | P2RY12, P2RY11, P2RY6 | GABRA1 2179/4885GABRG2 2601/4885GABRB3 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.